Evaluation of Pre-Treatment Serum Levels of IL-7 and GM-CSF in Colorectal Cancer Patients

Mehdi Taghipour Fard Ardekani1, Mahyar Malekzadeh1, Seyed Vahid Hosseini3, Elahe Bordbar1, Mehrnoosh Doroudchi∗1,2, Abbas Ghaderi1,2

1. Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
2. Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
3. Colorectal Research Center, Faghihi Hospital, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Submitted 16 Oct 2013; Accepted 15 Dec 2013

Survival of Colorectal cancer (CRC) patients is considerably stage-dependent; therefore, early diagnosis is a pivotal factor in decreasing mortality and morbidity associated with this cancer. GM-CSF and IL-7 are reported to increase in different cancers and we aimed to investigate the pre-treatment serum levels of GM-CSF and IL-7 in Iranian patients with colorectal cancer. 127 patients (68 males and 59 females) entered this study before receiving chemotherapy or radiotherapy. A control group of 50 healthy age/sex matched individuals (27 males and 23 females) were included in the study. The serum levels of GM-CSF and IL-7 were measured using commercial enzyme linked immunosorbent assays. A significantly higher level of GM-CSF was found in the sera of patients with colorectal cancer compared to healthy age/sex matched controls (P=0.013). However, there was no significant difference between the levels of IL-7 in sera of patients and controls. We observed a significant elevation in the level of GM-CSF in poorly differentiated tumors (P=0.024). Also a significant correlation between lymphatic invasion and the level of GM-CSF in sera of CRC patients was detected (P=0.01). We found an increase of the level of IL-7 in four patients presenting moderate stages of tumor concomitant with a decrease of the level of GM-CSF. It can be concluded that the increase of the level of GM-CSF is accompanied by CRC progression in Iranian patients. Potential therapeutic effect of IL-7 in this disease, however, needs further investigations.

Key words: Colorectal cancer, serum, GM-CSF, IL-7

Annually one million new cases of colorectal cancer (CRC) are diagnosed and half a million death occurs due to this cancer (1). It represents the third and second most common cancer in men and women respectively, (10% and 9.4% of all cancers, respectively) but its mortality is less in women than in men. The survival rate of CRC is significantly different in early stages versus
GM-CSF but not IL-7 Increases during CRC Progression
late stages (1). In fact, staging is the most important
factor in evaluating the prognosis of colorectal
cancer (2); therefore, early diagnosis and treatment
can reduce mortality and morbidity of this
cancer (1).

The immune system plays a dual role in the
defence and development of many tumors.
Interestingly, tumor cells may exploit or produce
effectors of the immune system for their own
advantage. Colony Stimulating Factors (CSFs) are
among the cytokines that are produced by cancer
cells as well as the immune system in the course of
tumorigenesis (3). Cytokines can also modulate
several processes involved in tumor progression
and metastasis, for example angiogenesis and the
production of metalloproteinases (4).

Granulocyte Macrophage-Colony Stimulating
Factor (GM-CSF) is a cytokine that acts as a
growth factor for white blood cells, and stimulates
bone marrow to produce granulocytes and
macrophages (5). GM-CSF is highly efficient in
inducing specific immune responses resulting in
tumor destruction (6). On the other hand, the
production of GM-CSF correlates with the increase of
recurrence rates in head and neck squamous cell
carcinoma, possibly due to an inhibition of immune
responsiveness (7). GM-CSF exerts an important
role in regulation of intestinal immune and
inflammatory responses (8). The establishment of
normal colon epithelium is under the tight
regulation of GM-CSF by controlling apoptosis and
proliferation of these cells; therefore, GM-CSF
deregulation is suggested to be a part of colon
carcinogenesis. Moreover, GM-CSF can decrease
apoptosis in colon cancer (9) and has a role in
growth and cancer spreading (10).

On the other hand, CRC cells with
microinstability (MSI) gene can generate abnormal
peptides that stimulate the secretion of cytokines
(including GM-CSF), the infiltration of lymphocytes and stimulate the immune system
against tumor, which can lead to a better prognosis
for the patients (6). An increase in the level of GM-
CSF in sera of colorectal cancer patients was shown
to correlate with tumor prognosis (5).

Another cytokine which is shown to be
produced by epithelial cells, keratinocytes, dendritic
cells, hepatocytes, neurons, but not lymphocytes is
Interleukin 7 (IL-7) (11). The expression of
functional IL-7 receptor (IL-7R) on epithelial tumor
cells including a colon cancer cell line was reported
(12). IL-7 is a glycoprotein that is normally secreted
by stromal cells in the red marrow and thymus and
stimulates the proliferation of pre-B and pro-B cells
while it supports the maturation of megakaryocytes
and stimulates the proliferation of early and mature
activated T-cells (13). It is responsible of increasing
the production of cytotoxic T cells and T killer cells
and induces proinflammatory cytokine secretion
and the anti-tumor activity of monocytes and T
cells (14). IL-7 also enhances the expression and
secretion of IL-3 and GM-CSF in activated human
T-cells and downregulates TGF-beta in macro-
phages, thereby accelerating anti-tumor immune
responses (15).

Experimental immunodeficient tumor-bearing
mice have provided the evidence of the anti-tumor
properties of recombinant human IL-7 (rhIL-7) on a
human colon tumor (16). In addition, vaccination of
patients with progressive colon cancer disease with
autologous tumor cells transfected with IL-7 and
GM-CSF genes could result in regression of tumor
in some patients (17). Conversely, IL-7 is reported
to be elevated in sera of patients with colorectal
cancer at stages III and IV. This notion has resulted
in considering IL-7 as a diagnostic or prognostic
factor in this cancer (18-20).

Increased GM-CSF mRNA, protein and its
receptor have been found in many colon cancer cell
lines, as well as in surgical specimens (21-22). GM-
CSF and Macrophage-Colony Stimulating Factor
(M-CSF) were reported to stimulate the metastatic
properties of carcinoma cell lines and correlate with
tumor prognosis (5, 23-24). There are few reports
that have examined GM-CSF in the pathogenesis of colorectal cancer, and the studies on the level of IL-7 in these patients are scarcer.

In the present study we aimed to determine the pre-treatment serum levels of GM-CSF and IL-7 in Iranian patients with CRC and investigate their possible correlation with clinicopathological characteristics of the patients. The potential diagnostic use of circulating GM-CSF and IL-7 and further clinical applications in Iranian patients with colorectal cancer were explored as preliminary data.

Materials and Methods

Patients

This study was approved by the Ethics Committee of Shiraz University of Medical Science (SUMS). The patients were informed about the aim of this study as well as safety and security measures before their consents were obtained. The cases were selected among CRC patients who were referred for surgery to hospitals related to SUMS between November 2009 and September 2010. 127 cases (68 males and 59 females) aged between 13-83 years entered the study. None of the patients had been treated by chemotherapy or radiotherapy before sample collection. The clinicopathological characteristics of the patient group is shown in table 1.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Number (127)</th>
<th>Percentage</th>
<th>Characteristics</th>
<th>Number (127)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor type</td>
<td></td>
<td></td>
<td>Lymph node inv.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>106</td>
<td>83.5</td>
<td>Is seen</td>
<td>38</td>
<td>29.9</td>
</tr>
<tr>
<td>Adenocarcinoma with mucin production</td>
<td>16</td>
<td>12.6</td>
<td>Not seen</td>
<td>60</td>
<td>47.3</td>
</tr>
<tr>
<td>other</td>
<td>5</td>
<td>3.9</td>
<td>Unknown</td>
<td>29</td>
<td>22.8</td>
</tr>
<tr>
<td>Histological grade</td>
<td></td>
<td></td>
<td>T</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well diff.</td>
<td>86</td>
<td>67.7</td>
<td>T1</td>
<td>08</td>
<td>06.3</td>
</tr>
<tr>
<td>Moderate diff.</td>
<td>17</td>
<td>13.4</td>
<td>T2</td>
<td>25</td>
<td>19.7</td>
</tr>
<tr>
<td>Poorly diff.</td>
<td>11</td>
<td>08.7</td>
<td>T3</td>
<td>55</td>
<td>43.3</td>
</tr>
<tr>
<td>Unknown</td>
<td>13</td>
<td>10.2</td>
<td>T4</td>
<td>18</td>
<td>14.2</td>
</tr>
<tr>
<td>Unknown</td>
<td>21</td>
<td></td>
<td>Unknown</td>
<td>21</td>
<td>16.5</td>
</tr>
<tr>
<td>Tumor size</td>
<td></td>
<td></td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diameter&gt;5cm</td>
<td>79</td>
<td>62.2</td>
<td>N0</td>
<td>57</td>
<td>44.9</td>
</tr>
<tr>
<td>Diameter&lt;5 cm</td>
<td>19</td>
<td>15</td>
<td>N1</td>
<td>22</td>
<td>17.3</td>
</tr>
<tr>
<td>Unknown</td>
<td>29</td>
<td>22.8</td>
<td>N2</td>
<td>16</td>
<td>12.6</td>
</tr>
<tr>
<td>Unknown</td>
<td>32</td>
<td></td>
<td>Unknown</td>
<td>32</td>
<td>25.2</td>
</tr>
<tr>
<td>Tumor side</td>
<td></td>
<td></td>
<td>M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right colon</td>
<td>13</td>
<td>10.2</td>
<td>M0</td>
<td>90</td>
<td>70.9</td>
</tr>
<tr>
<td>Left colon</td>
<td>84</td>
<td>66.2</td>
<td>M1</td>
<td>27</td>
<td>21.3</td>
</tr>
<tr>
<td>Unknown</td>
<td>30</td>
<td>23.6</td>
<td>Unknown</td>
<td>10</td>
<td>07.9</td>
</tr>
<tr>
<td>Perilymphatic inv.</td>
<td></td>
<td></td>
<td>Tumor stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is seen</td>
<td>26</td>
<td>20.5</td>
<td>Stage 1 (Low)</td>
<td>25</td>
<td>19.7</td>
</tr>
<tr>
<td>Not seen</td>
<td>98</td>
<td>77.1</td>
<td>Stage 2 (Low)</td>
<td>40</td>
<td>31.5</td>
</tr>
<tr>
<td>Unknown</td>
<td>3</td>
<td>2.4</td>
<td>Stage 3 (High)</td>
<td>23</td>
<td>18.1</td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td></td>
<td>Stage 4 (High)</td>
<td>30</td>
<td>23.6</td>
</tr>
<tr>
<td>Perineural inv.</td>
<td></td>
<td></td>
<td>Unknown</td>
<td>9</td>
<td>07.1</td>
</tr>
<tr>
<td>Is seen</td>
<td>14</td>
<td>11.0</td>
<td>Depth of invasion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not seen</td>
<td>110</td>
<td>86.6</td>
<td>mucosa and submucosa</td>
<td>07</td>
<td>05.5</td>
</tr>
<tr>
<td>Unknown</td>
<td>3</td>
<td>2.4</td>
<td>muscularis propria</td>
<td>27</td>
<td>21.3</td>
</tr>
<tr>
<td>Perivascular inv.</td>
<td></td>
<td></td>
<td>serosa &amp; subserosa</td>
<td>68</td>
<td>53.5</td>
</tr>
<tr>
<td>Is seen</td>
<td>18</td>
<td>14.2</td>
<td>Unknown</td>
<td>25</td>
<td>19.7</td>
</tr>
<tr>
<td>Not seen</td>
<td>106</td>
<td>83.4</td>
<td>Unknown</td>
<td>25</td>
<td>19.7</td>
</tr>
</tbody>
</table>

*Inv. = Involvement
GM-CSF but not IL-7 Increases during CRC Progression

The control group was selected from 50 healthy adults aged between 21-83 years (27 males and 23 females) who had no acute or chronic diseases such as autoimmune disease, diabetes mellitus, thyroid disease, recent common cold, hypertension, hyper-lipidemia, ischemic heart disease, cerebrovascular, renal, skin and pulmonary disorders as well as infectious diseases and were not receiving any medications.

The group of 127 CRC patients (68 males and 59 females) and 50 healthy controls (27 males and 23 females) were matched based on age and gender (Table 2). The mean age of the CRC patients was 54.27 ± 15.62 years and the mean age of healthy individuals was 54.38 ± 13.98 years. Similarly, the female/ male ratio in the CRC group was 0.87 and in control group was 0.85 (P= 0.956).

Samples

Four ml blood was collected from peripheral veins of patients on the day before surgery. The samples were brought to Shiraz Institute for Cancer Research (ICR) immediately. Samples were centrifuged and sera were preserved at -20°C till used. On the day of operation, the tissue biopsies were assessed by collaborative pathologist. The pathologist confirmed colon cancer and evaluated invasion of tumors to perineural, perivascular, perilymphatic and local area lymph nodes. Cancer was staged according to tumor-node-metastasis (TNM) by the American Joint Committee on Cancer Classification and stage grouping.

ELISA assays

The plasma level of GM-CSF was measured by a commercial enzyme linked immunosorbent assay (ELISA) (eBiosciences, Austria) according to the manufacturer's instructions. The sensitivity of this assay was 0.6 pg/ml and the range of detection was between 7.8-500 pg/ml. The serum level of IL-7 was measured using a commercial ELISA assay (Abcam, UK) according to the manufacturer's instructions. The sensitivity of this assay was less than 3 pg/ml and the range of detection was between 6.25-200 pg/ml.

Statistical analysis

Student's t-test was used for the analysis of age and gender distribution between the case and the control groups. One-way ANOVA or t-test was used for the comparisons between the two groups using SPSS software (11.5, Chicago, Illinois). When the data points were less than 30 in categories, the normality of data was checked and parametric or non parametric (Kruskal-Wallis and Mann-Whitney) analyses were performed. Statistically significant differences were defined as comparisons resulting in p<0.05.

Results

A significantly higher level of GM-CSF (12.49±27.28 pg/ml) was found in the sera of patients with colorectal cancer compared with healthy age/sex matched controls (2.21 ± 15.68 pg/ml), (P= 0.013). Due to the high variance of data the analysis was performed by non-parametric comparison of the means (Mann-Whitney) and the results were confirmed (P=0.000). However, there

<table>
<thead>
<tr>
<th>Table 2. The age and gender distribution among patients and controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>----------------------</td>
</tr>
<tr>
<td>Case</td>
</tr>
<tr>
<td>normal</td>
</tr>
<tr>
<td>Total</td>
</tr>
<tr>
<td>P value</td>
</tr>
</tbody>
</table>

29 Int J Mol Cell Med Winter 2014; Vol 3 No 1
was no significant difference between the level of IL-7 in sera of patients (0.16 ± 1.38 pg/ml) and healthy controls (0.06 ± 0.16 pg/ml) which was also confirmed by the non-parametric statistical evaluation (P=0.088). A high percentage of CRC patients (73 out of 124, 59%) had some level of GM-CSF in their sera while only one out of 50 (2%) healthy controls were found positive for GM-CSF (Roc curve cut off point= 5.04 pg/ml). Conversely, a higher number of healthy controls (7 out of 50, 14%, figure 1) had some level of IL-7 in their sera compared to the CRC patients (4 out of 124, 3.23%, figure 1).

We observed a significant difference (P=0.024) in the serum level of GM-CSF in patients with different histological grades of colorectal cancer. The level of GM-CSF showed an increasing trend with the loss of differentiation in the tumor. Conversely, the highest level of IL-7 was detected in patients with well differentiated tumors and no IL-7 was detected in patients with poorly differentiated tumors (Table 3).

A significant difference in the level of GM-CSF in sera of CRC patients with or without lymphatic invasion was also observed (P= 0.01). Accordingly, the level of GM-CSF was much higher in sera of patients with lymphatic invasion compared to those without lymphatic invasion (Table 4). No difference was observed in the level of IL-7 between the two groups of CRC patients.
We also compared the level of the two cytokines between CRC patients presenting low stages (Stages 1 and 2), medium stages (Stages 3a and 3b) and high stages (stages 3c and 4) tumors. We found a significant increase in the level of IL-7 in moderate stage tumors (P<0.05). This increase was concomitant with a decrease in the level of GM-CSF in sera of the patients with medium stage tumors (Figure 2).

The mean serum levels of GM-CSF did not show any difference between male (9.49 ± 8.80 pg/ml) and female (15.81 ± 38.36 pg/ml) CRC patients. There was also no significant difference between the level of IL-7 in male (0.04 ± 0.28 pg/ml) and female (0.29 ± 1.98 pg/ml) patients.

There was no significant correlation between tumor type, tumor side, tumor size, perineural invasion, vascular invasion and lymph node involvement with either of GM-CSF or IL-7 cytokines levels.

### Discussion

In this study we observed a significantly higher level of GM-CSF in Iranian patients with CRC compared to their age/sex matched controls. Previous studies have shown that the increased level of local cytokines in the site of tumor stimulates the immune system against tumor and CSFs have the most important role in this event (3). On the other hand, cytokines and growth factors produced by cancer cells or the stroma of tumor stimulate tumor growth and invasiveness (10). The detection of CSF receptors in several solid tumor cells including CRC cells may contribute to the stimulation of tumor by these cytokines (9). In a few investigations in other populations the level of GM-CSF in sera of CRC patients has been quite variable. One study has shown that elevated level of GM-CSF in sera of CRC patients does not correlate with prognosis or clinical features of CRC (5). A study found no GM-CSF in sera of CRC patients (25), while another group found a slight elevation of GM-CSF level in sera of CRC patients (26). It is shown that CRC cells not only express GM-CSF receptor but also secrete GM-CSF thereby stimulating their own proliferation (3). The odd, however, is that combining GM-CSF with chemotherapy leads to better treatment of many solid tumors with a mild inhibition of angiogenesis or moderate apoptosis in CRC cells (27-29). Moreover, colon cancer cells genetically engineered to secrete GM-CSF, have been shown to afford specific and long-lasting anti-tumor immunity (6).

The exact explanation for the variable results on the production of GM-CSF in CRC and the mechanisms behind its dual (or multiple) role against tumor cells is not known. However, it has been suggested that a slight elevation in the serum GM-CSF levels may reflect a protective response in cancer patients, while higher levels of autologous GM-CSF may stimulate the metastatic properties of cancer cells (26). Accordingly, the addition of recombinant GM-CSF at doses ranging between 30 pg/ml and 30 ng/ml did not appear to affect the

### Table 3. Well differentiated colorectal tumors induced more IL-7 production in the patients

<table>
<thead>
<tr>
<th>Histological grade</th>
<th>N</th>
<th>IL-7 Mean ± SD</th>
<th>GM-CSF Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well differentiated</td>
<td>86</td>
<td>0.20 ±1.65</td>
<td>10.14 ± 10.80</td>
</tr>
<tr>
<td>Moderately differentiated</td>
<td>17</td>
<td>0.16 ± 0.52</td>
<td>12.10 ± 20.39</td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>11</td>
<td>0</td>
<td>33.94 ± 81.83</td>
</tr>
<tr>
<td>P-value</td>
<td>114</td>
<td>0.911</td>
<td>0.024*</td>
</tr>
</tbody>
</table>

*Statistical significance when compared to histological grade.
poliferation of colorectal cancer cell lines in culture (22).

A previous report showed that the level of IL-8 but not GM-CSF was significantly different between the well differentiated adenocarcinomas and other types of colorectal tumors (26), however, we found a significant correlation between the level of GM-CSF and the histological grade of the tumors. The poorly differentiated tumors were associated with an increase of the level of GM-CSF in the sera of patients. This was accompanied by the correlation of lymphatic invasion of the tumor and the level of GM-CSF.

In our study, IL-7 was only elevated in 4 CRC patients and did not differ between patients and controls. Despite the low number of IL-7 positive CRC patients, an inverse pattern of GM-CSF and IL-7 increase was observed in the four IL-7 positive cases. Increase of IL-7 was accompanied by a decrease of the GM-CSF in those patients. The low number of IL-7 positive cases hampers to draw any conclusion but it may be suggestive of a beneficial role of IL-7 in CRC. It can also be a part of efforts of the immune system to respond to the tumor. There is limited information on the level of IL-7 in colorectal cancer and the results of the available studies are contradictory.

In one study, IL-7 was only detectable in higher stages of the tumor. In our hands, IL-7 was only produced by tumors in stage 3a where the production of GM-CSF decreased. On the contrary, there are other reports showing that IL-7 is increased in colorectal cancer and it can be used as a diagnostic or prognostic factor in this cancer (18-20). Moreover, the transition from stage 3 to stage 4 of colorectal cancer is characterized by an increase of the serum level of IL-7 (18-20).

The mean concentrations of both IL-7 and GM-CSF are reported to be high in females with colorectal cancer but did not reach the significant level (10). Mroczko et al. observed higher serum levels of IL-3, GM-CSF and M-CSF in males in comparison to females, but again, these differences were not significant (10). Our results, however, did not show any difference between the levels of GM-CSF and IL-7 in male and female patients.

Currently it is difficult to interpret the discrepancy of the IL-7 data obtained in our study and some previous studies but as mentioned by others, what actually operate in vivo are the cytokine cascades and cytokine networks (26). In addition, part of these differences may be due to the diversity of the cells of a specific tumor type in different patients. Moreover, as shown for breast tumor cells, even in the same host, tumor cells show transcriptional diversity (30). Therefore, obtaining a consensus pattern of cytokine production by colorectal (and other) tumor cells in different individuals needs the evaluation of a broader range of cytokines in a greater number of patients.

We did not find any correlation between tumor type, tumor side, tumor size, perineural invasion, vascular invasion, and lymph node involvement with either GM-CSF or IL-7 cytokines. Similarly, another study reported no correlation between the serum levels of GM-CSF and the clinicopathological findings in colorectal cancer (26).

### Table 4. Higher levels of GM-CSF in sera of colorectal cancer patients with lymphatic invasion compared to those without lymphatic invasion.

<table>
<thead>
<tr>
<th>Lymphatic invasion</th>
<th>N</th>
<th>IL-7 [Mean ± SD]</th>
<th>GM-CSF [Mean ± SD]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is seen</td>
<td>26</td>
<td>0.08 ± 0.43</td>
<td>24.49 ± 53.52</td>
</tr>
<tr>
<td>Not seen</td>
<td>98</td>
<td>0.18 ± 1.54</td>
<td>9.31 ± 12.52</td>
</tr>
<tr>
<td>P-value</td>
<td>124</td>
<td>P = 0.752</td>
<td>P = 0.01*</td>
</tr>
</tbody>
</table>

*P < 0.05
GM-CSF but not IL-7 Increases during CRC Progression

In summary, due to a high percentage of patients with elevated serum level of GM-CSF, we suggest that GM-CSF can be used as a tumor marker in Iranian colorectal cancer patients, however, the specificity and sensitivity of the test should be defined in future studies. We also suggest that the role of IL-7 in colorectal cancer needs more investigation and may provide a new target in the immunotherapy of colorectal cancer.

Acknowledgments

This work, as a part of thesis project of Mehdi Taghipour Fard Ardekani (MD), was funded by a grant (1923) from Shiraz University of Medical Sciences and Shiraz Institute for Cancer Research (ICR-100-502). Funding sources had no influence over the study design, data collection, analysis or interpretation or manuscript preparation and submission.

Conflict of interest

Authors declared no conflict of interest.

References